<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pure erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (PEL) is rare, characterized by a neoplastic proliferation of erythroblasts </plain></SENT>
<SENT sid="1" pm="."><plain>Given recent incorporation of molecular genetic findings and clinical features in the revised 2008 World Health Organization classification scheme of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, we questioned if PEL still remains as a distinct subtype of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In this retrospective study, we identified 18 cases of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> with morphologic and immunophenotypic features of PEL </plain></SENT>
<SENT sid="3" pm="."><plain>Following the current World Health Organization classification algorithm, these cases were classified as: 13 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes, 3 therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, and 1 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e>, and one unclassifiable due to insufficient clinical information </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 16 cases with cytogenetic data harbored an extremely complex karyotype and the median overall survival of the 18 patients was 3 months (range, 1-7 months) </plain></SENT>
<SENT sid="5" pm="."><plain>This survival was significantly shorter than that of patients with <z:hpo ids='HP_0011009'>acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, erythroid/myeloid subtype, or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes with erythroid predominance (P&lt;0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>PEL is characterized as a neoplastic erythroid hyperproliferation with maturation arrest </plain></SENT>
<SENT sid="7" pm="."><plain>E-cadherin emerged as the most sensitive and specific marker for immature erythroblasts, and was helpful in distinguishing PEL from other erythroid proliferations </plain></SENT>
<SENT sid="8" pm="."><plain>Our study showed that the criteria for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> in the 2008 World Health Organization system facilitate reclassification of PEL cases into other <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> categories, mainly of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes </plain></SENT>
<SENT sid="9" pm="."><plain>These new assigned categories fail to capture the distinct features of PEL, where the phenotype of PEL correlates with a very complex karyotype and an extremely aggressive clinical course </plain></SENT>
</text></document>